NASDAQ:CYANCyanotech Stock Price, Forecast & News

Cyanotech's stock was trading at $1.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYAN stock has increased by 8.0% and is now trading at $2.15. View which stocks have been most impacted by Coronavirus.

Cyanotech is scheduled to release its next quarterly earnings announcement on Monday, July 6th 2020. View our earnings forecast for Cyanotech.

Cyanotech Corp (NASDAQ:CYAN) posted its quarterly earnings results on Tuesday, February, 11th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $7.50 million for the quarter. Cyanotech had a negative net margin of 4.12% and a negative return on equity of 7.93%. View Cyanotech's earnings history.

Media headlines about CYAN stock have trended very negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cyanotech earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutCyanotech.

Cyanotech saw a increase in short interest in May. As of May 15th, there was short interest totaling 8,000 shares, an increase of 233.3% from the April 30th total of 2,400 shares. Based on an average trading volume of 13,500 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.2% of the company's shares are short sold. View Cyanotech's Current Options Chain.

Some companies that are related to Cyanotech include Natural Alternatives International (NAII), Mannatech (MTEX), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyanotech investors own include Clarivate Analytics (CCC), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Bausch Health Companies (BHC), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), NovaBay Pharmaceuticals (NBY) and NovaBay Pharmaceuticals (NBY).

Cyanotech trades on the NASDAQ under the ticker symbol "CYAN."

Cyanotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.25%). View institutional ownership trends for Cyanotech.

CYAN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Cyanotech.

Shares of CYAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYAN stock can currently be purchased for approximately $2.15.

Cyanotech has a market capitalization of $12.75 million and generates $30.20 million in revenue each year. Cyanotech employs 118 workers across the globe.

The official website for Cyanotech is www.cyanotech.com.

Cyanotech's mailing address is 73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA KONA HI, 96740. The biotechnology company can be reached via phone at 808-326-1353 or via email at [email protected]